CD8A and neoplasm: Mechanistically, TOPK suppressed IRF5 expression and HI-TOPK-032 restored CD8<sup>+</sup> T cell cytotoxicity in vitro and, with anti-PD-1, further inhibited tumor growth and increased intratumoral cytokine production.